# Case report: A novel perspective on the treatment of primary tracheal small cell carcinoma: a patient’s experience with immuno-combined EP therapy and literature review

## TL;DR

A patient with tracheal small cell carcinoma was successfully treated with immuno-combined EP therapy, offering new insights into managing this rare cancer.

## Contribution

The paper presents a novel treatment approach using immuno-combined EP therapy for tracheal small cell carcinoma.

## Key findings

- The patient experienced significant symptom relief and disappearance of the tracheal mass after six cycles of treatment.
- The treatment aligns with the CAPSTONE-1 study's methodology and shows promise for similar cases.
- The case study is supported by a comprehensive literature review to contextualize the findings.

## Abstract

Tracheal small cell carcinoma (SCC) is a rare malignancy, for which the optimal treatment strategy has yet to be determined. Currently, treatment largely aligns with the therapeutic guidelines established for small cell lung cancer, although numerous unresolved issues remain. This paper details a case study of a patient with Stage IIIB primary tracheal SCC, who was treated with an immune-combined etoposide-platinum(EP) regimen. This treatment offers valuable insights into innovative approaches for managing such malignancies. Furthermore, the study includes a comprehensive literature review to better contextualize the findings. The patient, admitted on May 2, 2023, had been experiencing persistent symptoms of airway discomfort for 15 days. A bronchoscopy performed on May 4 revealed tracheal SCC, classified as T4N2M0, IIIB. Following the CAPSTONE-1 study’s methodology, the patient underwent six cycles of PD-L1(adebrelimab) combined with EP therapy, leading to significant relief of symptoms and the eventual disappearance of the tracheal mass.